Monashee Investment Management LLC Has $15.65 Million Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Monashee Investment Management LLC raised its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 12.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 225,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Structure Therapeutics accounts for about 8.8% of Monashee Investment Management LLC’s holdings, making the stock its biggest holding. Monashee Investment Management LLC owned about 0.37% of Structure Therapeutics worth $15,649,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. CWM LLC raised its position in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares during the period. State of Wyoming acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $28,000. Banque Cantonale Vaudoise acquired a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $205,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $206,000. 91.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on GPCR. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Citizens Jmp decreased their price target on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research note on Friday, February 27th. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and an average target price of $106.75.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $43.30 on Friday. The business has a 50 day simple moving average of $43.79 and a 200 day simple moving average of $57.28. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The stock has a market capitalization of $3.08 billion, a P/E ratio of -49.77 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. Equities analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.